Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Illumina Inc (NASDAQ: ILMN) is described by the company as a global leader in DNA sequencing and array-based technologies, serving research, clinical, and applied markets across genomics, multiomics, and proteomics. This news page aggregates recent press releases and announcements so readers can follow how Illumina’s technologies, collaborations, and financial disclosures evolve over time.
Company news highlights include product and platform launches, such as Illumina Connected Multiomics, a cloud-based software platform for analyzing and visualizing multiomic data, and Illumina Protein Prep, which the company states delivers broad coverage of the blood proteome and supports large-scale genomics studies. Illumina has also announced the Illumina Billion Cell Atlas, a large genome-wide genetic perturbation dataset developed through its BioInsight business to support AI-driven drug discovery in collaboration with pharmaceutical partners.
Investors can use this news feed to track Illumina’s preliminary financial results, earnings announcements, and capital markets activities, as reflected in press releases tied to quarterly and annual results and conference presentations. The page also captures updates on strategic agreements and acquisitions, including Illumina’s planned acquisition of Standard BioTools’ aptamer-based and functional proteomics business, as described in SEC filings and related communications.
In addition, Illumina’s news often covers leadership appointments, regulatory and market developments, and collaborations with genomics and population health partners such as MyOme. By reviewing these updates in one place, readers can better understand how Illumina positions its sequencing, multiomic, and proteomic offerings and how its corporate strategy and partnerships may influence its role in genomics and precision medicine. Bookmark this page to review new company-issued information as it becomes available.
Illumina (NASDAQ:ILMN) faces a setback as the European Commission prohibits its acquisition of GRAIL, despite prior support from the US Federal Trade Commission. The company plans to appeal this decision, asserting that the merger would enhance access to GRAIL's early cancer detection test, Galleri. Illumina claims the combined entity could save tens of thousands of lives and billions in healthcare costs in the EU. Additionally, the company is reviewing strategic alternatives for GRAIL amid the ongoing regulatory challenges.
Illumina, Inc. (NASDAQ:ILMN) achieved a significant victory with a favorable ruling from the Administrative Law Judge in the FTC's challenge to its acquisition of GRAIL. The ALJ's decision dismissed the FTC's claims that the acquisition would harm competition in the multi-cancer early detection (MCED) market. The merger aims to enhance the accessibility of GRAIL's Galleri test, which is crucial for early cancer detection. Illumina's CEO emphasized this integration as a key step toward making life-saving diagnostics affordable for everyone.
Illumina (NASDAQ: ILMN) has opened its first manufacturing facility in Shanghai, China, aimed at enhancing local production of gene sequencing instruments and consumables. This site is expected to serve increasing demand in the Chinese market and become Illumina's third-largest global production operation. The facility will initially produce 16 sequencing reagents for clinical use, with full localization projected within five years. This investment underscores Illumina's commitment to China's life sciences sector and aims to increase efficiency in its global supply chain.
Illumina (NASDAQ: ILMN) will host the inaugural Illumina Genomics Forum (IGF) from September 28 to October 1 in San Diego. The event features Chris Evert, who will discuss her personal battle with ovarian cancer and the role of genomics in early detection and treatment. Notable speakers include former President Barack Obama and Bill Gates. Key themes will explore how genomic technology is transforming patient care and enhancing health outcomes. The IGF aims to address pivotal issues in cancer treatment and improve accessibility to genomic health care.
Illumina will feature Anne Wojcicki, CEO of 23andMe, at its inaugural Illumina Genomics Forum in San Diego from September 28 to October 1, 2022. Wojcicki's session, 'Disruption Ahead,' will focus on empowering consumers in health care through genomics. She will discuss her experience in disrupting traditional health care and the acquisition of Lemonaid Health for enhanced individualized primary care. The forum will also include talks by former President Obama and Bill Gates, highlighting equitable health care and the potential of genomics in improving global health.
Minderoo Foundation and Illumina (NASDAQ: ILMN) announced a three-year partnership worth 40 million Australian dollars (USD 27.8 million) to enhance marine biodiversity research using advanced genomics. The collaboration aims to revolutionize marine conservation by employing environmental DNA (eDNA) technologies and high-throughput sequencing aboard research vessels. This initiative seeks to improve the understanding of marine ecosystems and contribute valuable data for conservation efforts amidst changing environmental conditions.
Illumina announced the inaugural Illumina Genomics Forum (IGF) to be held in San Diego from September 28 to October 1, 2022. The forum will include a conversation with Dr. Karen Knudsen, CEO of the American Cancer Society, focusing on the role of clinical genomics in oncology. Former U.S. President Barack Obama and Bill Gates are also slated to speak on health equity and the potential of genomics, respectively. Key themes include advancements in patient care and the impact of genomics on healthcare.
Illumina reported Q2 2022 revenue of $1.16 billion, a 3% increase year-over-year. However, the company faced a GAAP diluted loss per share of $(3.40), primarily due to $609 million in legal contingencies. Non-GAAP diluted EPS was $0.57, down from $1.87 in Q2 2021. For fiscal year 2022, revenue growth is expected at 4% to 5%, with anticipated GAAP diluted losses between $(2.93) and $(2.78). Despite revenue growth, ongoing legal issues and delays in customer lab expansions pose challenges.
Illumina (NASDAQ: ILMN) will host the Illumina Genomics Forum in San Diego from September 28 to October 1, featuring keynote speaker Bill Gates from the Bill & Melinda Gates Foundation. The forum will focus on achieving health equity through genomics and include a panel titled "Making 'Genomics for All' More than a Mantra." Additional discussions will explore how genomic technology can enhance patient care and support healthcare's quadruple aim. Other key speakers include former President Barack Obama, who will discuss healthcare equity and accessibility.
Illumina Ventures, in partnership with Illumina (NASDAQ: ILMN), strengthens its European operations by adding four new team members. The new hires include Arnaud Autret as Head of European Operations, William Byrne as an Associate, and Venture Advisors Ronan Byrne and Ivan Coulter. This expansion aims to bolster their focus on genomics-focused projects across Europe, enhancing their support for startups in clinical diagnostics and life sciences. The firm, dedicated to investing in innovative healthcare solutions, continues to pursue growth and transformation in the healthcare landscape.